M ENTRECTINIB (is an active metabolite) | ENTRECTINIB | ATC L01XE56
ANTINEOPLASTIC A TROPOMYOSIN RECEPTOR TYROSINE KINASES INHIBITOR (TRK) TRKA, TRKB, AND TRKC PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS1 INHIBITOR ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITOR ALSO INHIBITS JAK2 AND TNK2 TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | - | Cmax 1.25 MICROMOLAR VD 81.1 LITER PPB 99 PERCENT Cl 52.4 LITER / HOUR HT 40 HOUR | TROPOMYOSIN RECEPTOR TYROSINE KINASES INHIBITOR (TRK) TRKA TRKB AND TRKC PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ROS1 ANAPLASTIC LYMPHOMA KINASE (ALK) | High affinity nerve growth factor receptor inhibitor P04629 (NTRK1_HUMAN) | EMA ANSM (in French) Inxight Drugs Dailymed Drugs.com SIDER side effects Chemical Probes Portal ChEMBL BindingDB DrugBank |